Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-2

Pralmorelin, Growth Hormone Releasing Peptide-2, KP-102

Quick Stats
Studies 230
Trials 1
Score 3
2012 pubmed 14 citations

Growth hormone response to growth hormone-releasing peptide-2 in growth hormone-deficient little mice.

Peroni. Cibele N CN; Hayashida. Cesar Y CY; Nascimento. Nancy N; Longuini. Viviane C VC; Toledo. Rodrigo A RA; Bartolini. Paolo P; Bowers. Cyril Y CY; Toledo. Sergio P A SP

Key Findings

  • GHRP‑2 raised GH levels in GH‑deficient (lit/lit) mice by about 9 ng/ml, far above the control level.
  • The GH response was dose‑dependent: heterozygous (lit/+) mice showed a moderate rise, while wild‑type mice had a large increase.
  • The effect appears to be mediated by the ghrelin receptor (GHSR‑1a) rather than the GHRH receptor.

Practical Outcomes

  • For biohackers, this study supports the idea that GHRP‑2 can boost growth hormone even when the usual GHRH pathway is impaired, suggesting it works via a direct ghrelin‑receptor mechanism. While the research is in mice, it reinforces the rationale for using GHRP‑2 as a GH‑stimulating peptide in humans, especially for those seeking a reliable way to increase GH without relying on GHRH analogues. However, dosing and safety still need human‑specific data.

Summary

In a mouse model that can’t release growth hormone normally because its growth‑hormone‑releasing hormone (GHRH) receptors are broken, a single injection of the peptide GHRP‑2 still caused a measurable rise in growth‑hormone levels. The effect was smaller than in normal mice but clearly above baseline, showing that GHRP‑2 can trigger hormone release through a different pathway that doesn’t need GHRH.

Abstract

To investigate a possible direct, growth hormone-releasing, hormone-independent action of a growth hormone secretagogue, GHRP-2, in pituitary somatotroph cells in the presence of inactive growth hormone-releasing hormone receptors. The responses of serum growth hormone to acutely injected growth hormone-releasing P-2 in lit/lit mice, which represent a model of GH deficiency arising from mutated growth hormone-releasing hormone-receptors, were compared to those observed in the heterozygous (lit/+) littermates and wild-type (+/+) C57BL/6J mice. After the administration of 10 mcg of growth hormone-releasing P-2 to lit/lit mice, a growth hormone release of 9.3±1.5 ng/ml was observed compared with 1.04±1.15 ng/ml in controls (p<0.001). In comparison, an intermediate growth hormone release of 34.5±9.7 ng/ml and a higher growth hormone release of 163±46 ng/ml were induced in the lit/+ mice and wild-type mice, respectively. Thus, GHRP-2 stimulated growth hormone in the lit/lit mice, and the release of growth hormone in vivo may be only partially dependent on growth hormone-releasing hormone. Additionally, the plasma leptin and ghrelin levels were evaluated in the lit/lit mice under basal and stimulated conditions. Here, we have demonstrated that lit/lit mice, which harbor a germline mutation in the Growth hormone-releasing hormone gene, maintain a limited but statistically significant growth hormone elevation after exogenous stimulation with GHRP-2. The present data probably reflect a direct, growth hormone-independent effect on Growth hormone S (ghrelin) stimulation in the remaining pituitary somatotrophs of little mice that is mediated by growth hormone S-R 1a.

Study Information

Provider

pubmed

Year

2012

Date

2012-03-01T00:00:00.000Z

DOI

10.6061/clinics/2012(03)11

Citations

14

References

68